563 filings
Page 3 of 29
SC 13D/A
NGNE
Neurogene Inc
20 Dec 23
Neurogene / BAKER BROS. ADVISORS ownership change
5:24pm
8-K
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
425
NGNE
Neurogene Inc
6 Dec 23
Business combination disclosure
4:24pm
8-K
NGNE
Neurogene Inc
6 Dec 23
Other Events
4:21pm
425
NGNE
Neurogene Inc
4 Dec 23
Business combination disclosure
5:14pm
8-K
NGNE
Neurogene Inc
4 Dec 23
Other Events
5:10pm
425
NGNE
Neurogene Inc
30 Nov 23
Business combination disclosure
4:06pm
EFFECT
NGNE
Neurogene Inc
14 Nov 23
Notice of effectiveness
12:15am
10-Q
2023 Q3
NGNE
Neurogene Inc
Quarterly report
14 Nov 23
12:00am
SEC STAFF LETTER
NGNE
Neurogene Inc
13 Nov 23
SEC staff letter
12:00am
S-4/A
NGNE
Neurogene Inc
Registration of securities issued in business combination transactions (amended)
8 Nov 23
2:34pm
CORRESP
NGNE
Neurogene Inc
8 Nov 23
Correspondence with SEC
12:00am
CORRESP
NGNE
Neurogene Inc
8 Nov 23
Correspondence with SEC
12:00am
S-4/A
NGNE
Neurogene Inc
Registration of securities issued in business combination transactions (amended)
18 Oct 23
4:09pm
CORRESP
NGNE
Neurogene Inc
18 Oct 23
Correspondence with SEC
12:00am
SC 13D/A
NGNE
Neurogene Inc
10 Oct 23
Neoleukin Therapeutics / BAKER BROS. ADVISORS ownership change
4:42pm
4
Baker Bros. Advisors
10 Oct 23
Neoleukin Therapeutics / JULIAN BAKER ownership change
4:22pm
UPLOAD
NGNE
Neurogene Inc
10 Oct 23
Letter from SEC
12:00am
SEC STAFF LETTER
NGNE
Neurogene Inc
10 Oct 23
SEC staff letter
12:00am
425
NGNE
Neurogene Inc
5 Oct 23
Business combination disclosure
12:50pm